Compare Moderna, Inc. (MRNA) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: Moderna, Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | VCIT | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Fixed Income |
52-Week High | $81.80 | $84.82 |
52-Week Low | $22.36 | $81.45 |
Enterprise Value | $19.70B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
